Please assess the completion status of the following clinical trial:

Trial Title: 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18 and 85, and undergoing a total knee or hip replacement.~2. Fluent in English, decision competent, willing and able to provide written informed consent, and able to complete the study's schedule of assessments.~3. Able to walk \>3m without an assisting device.~4. Have a BMI ≤ 40 kg/m2.~Exclusion Criteria:~1. Current participation in another orthopedic/Physical Therapy/rehab/anesthesiology interventional clinical trial.~2. Are at significant behavioral risks or have refractory major psychiatric disorders.~3. Revision surgery on the same extremity.~4. Have an American Surgical Association (ASA) Physical Status classification of 4 or higher.~5. Have been diagnosed with clinically significant neuropathy with its origins in either diabetes or other causes; have neuromuscular disease that would influence data collection.~6. Have a surgically-fused lumbar spine, or a spinal cord simulator, or other condition that would contraindicate or prohibit the conduct of spinal anesthesia.~7. At significant risk for postoperative substance abuse, or immediate-postoperative substance abuse withdrawal symptoms (alcohol, cocaine, enrolled in methadone or buprenorphine opioid withdrawal programs, etc.) Previous or current use of marijuana will not be an exclusion for study enrollment.~8. Are undergoing Total Knee Arthroplasty (TKA)/Total Hip Arthroplasty (THA) for a tumor.~9. Have contraindications (e.g., anaphylaxis) to any of the study drugs.~10. Have a systemic fungal infection.~11. Have a known hypersensitivity to bupivacaine hydrochloride or to any local anesthetic of the amide-type or to other components of bupivacaine hydrochloride solutions.~12. Have a known or suspected buprenorphine hypersensitivity (not including nausea and/or vomiting).~13. Have a gastro-intestinal (GI) obstruction.~14. Have paralytic ileus.~15. Pregnant women~16. Have had a kidney or liver transplant.~Veterans will not be excluded from participation based on smoking status, diagnosis of obstructive sleep apnea, or baseline monitored consumption of therapeutic opioids for documented medical indications; instead, these variables will be codified and quantified for subsequent covariate statistical analysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone) (Type: EXPERIMENTAL): Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
- Bupivacaine Only (control arm) (Type: ACTIVE_COMPARATOR): Patients will receive a nerve block consisting of bupivacaine only.

Based on this trial design, predict the completion outcome and termination type (if applicable).